The alcoholic liver disease/nonalcoholic fatty liver disease (ANI) scoring system was constructed as a response to a clinical need for avoiding the risks of liver biopsy in diagnosing the etiology of fatty liver disease.
Dr Ivana Cerovic and colleagues tested the reliability of ANI as a noninvasive method to distinguish alcoholic liver disease from nonalcoholic fatty liver disease.
The team classified 135 patients into 2 groups, of alcoholic liver disease and nonalcoholic fatty liver disease, according to the pathohistological results.
The team examined parameters for ANI that are aspartate aminotransferase, alanine aminotransferase, mean corpuscular volume, BMI, and sex.
ANI was calculated using an online calculator, official site of Mayo Clinic.
ANI was significantly higher in patients with alcoholic liver disease than nonalcoholic fatty liver disease.
|The cutoff point of the scoring system is −0.66|
|European Journal of Gastroenterology & Hepatology|
The cutoff point of ANI is −0.66.
The researchers found that ANI greater than −0.66 indicates alcoholic liver disease, whereas ANI less than −0.66 yields a higher probability of non alcoholic fatty liver disease with high specificity and sensitivity.
The mean corpuscular volume and aspartate aminotransferase/alanine aminotransferase ratio were higher, whereas BMI was lower in patients with alcoholic liver disease than in nonalcoholic fatty liver disease.
Dr Cerovic's team concludes, "The ANI scoring system may be used for the estimation of alcoholic origin of steatosis/steatohepatitis and may help in triaging patients for liver biopsy."
"ANI less than −0.66 indicates nonalcoholic fatty liver disease, whereas ANI greater than −0.66 confirms the alcoholic etiology, but does not exclude the contribution of associated factors toward the development of fatty liver in a Serbian population."